Smoldering Multiple Myeloma Committee Report

María-Victoria Mateos, MD, PhD

University of Salamanca, Spain

Shaji Kumar, MD Mayo Clinic

Diagnosis

• Stress importance of confirmation of numbers – also confirms stability/opportunity to observe evolution

• Patients with risk of progression >=80% @ 2 years were reclassified as active MM in 2014

• New risk stratificationhas the highest risk group with progression risk of 72% at the highest, a small group of patients –reclassification?

• Distinction between MGUS and SMM – important form a clinical standpoint, biology is a continuum

Endpoints for trials

• What would be the right endpoint for trials?

– Overall survival is the gold standard but will take many years to find the benefit

• Progression free survival?

• Sustained MRD negativity? If so, how long?

• HRQOL endpoints?